Physician profile
Dustin Dale Dinning
NPI 1578774022
$311,324.49
in general payments reported to CMS, 2019-2025
32 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $28K · 2021: $71K · 2022: $77K · 2023: $51K · 2024: $4,626 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Honoraria: $15K · Travel and Lodging: $6,380 · Food and Beverage: $3,870 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,275.00 |
| Honoraria | $15,312.50 |
| Travel and Lodging | $6,379.93 |
| Food and Beverage | $3,869.99 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $110,627.92 | 2019-2025 | Rinvoq |
| Horizon Therapeutics Plc | $84,690.72 | 2019-2023 | Krystexxa |
| Amgen INC. | $58,681.83 | 2019-2025 | Krystexxa, Otezla, Enbrel |
| Lilly USA, LLC | $45,866.26 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Novartis Pharmaceuticals Corporation | $8,296.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,010.29 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $472.54 | 2021-2025 | Saphnelo, Enhertu |
| Ucb, INC. | $361.88 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $250.81 | 2021-2025 | Tremfya, Simponi Aria, Tecvayli |
| Glaxosmithkline, LLC. | $230.01 | 2019-2025 | Benlysta, Nucala |
| Fresenius Kabi USA, LLC | $122.70 | 2023-2024 | Idacio |
| Pfizer INC. | $107.35 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $55.83 | 2023 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $47.53 | 2024-2025 | Keytruda |
| Organon LLC | $47.38 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $46.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.68 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $40.93 | 2022-2024 | Strensiq |
| Mallinckrodt Hospital Products INC. | $39.14 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $36.30 | 2019 | |
| Aurinia Pharma U.S., INC. | $27.65 | 2021 | |
| Sobi, INC | $27.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.36 | 2023 | Ninlaro |
| Genentech USA, INC. | $23.88 | 2024 | Perjeta, Phesgo, Actemra |
| Tersera Therapeutics LLC | $22.36 | 2024 | Zoladex |
| Kyowa Kirin, INC. | $21.65 | 2024 | Crysvita |
| Accord Healthcare, INC. | $21.40 | 2025 | |
| Radius Health, INC. | $17.69 | 2021 | |
| Boston Scientific Corporation | $16.93 | 2021 | |
| Pacira Therapeutics, INC. | $16.20 | 2020 | |
| Spectrum Pharmaceuticals INC. | $14.54 | 2023 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.08 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Dinning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.